Drop Testosterone (T) on Day 1
In the treatment of advanced prostate cancer (APC)
FIRMAGON® takes a more direct path to testosterone suppression than Leuprolide
FIRMAGON rapidly lowered T, nearly 90% on the first day
By day 28 of treatment, both FIRMAGON and Leuprolide achieved similar testosterone levels.
FIRMAGON gets you to T goal quickly
96% of FIRMAGON patients reached goal testosterone levels by day 3
Leuprolide initially increased testosterone levels—65% by the third day, compared to a 94% reduction with FIRMAGON. Some patients may require additional medication to prevent a symptomatic flare with Leuprolide.
TESTOSTERONE LEVELS IN THE FIRST 28 DAYS OF THERAPY
FIRMAGON (N=207)
Leuprolide (N=201)
FIRMAGON dropped PSA levels*
PSA (prostate-specific antigen) reduction follows testosterone suppression. FIRMAGON dropped PSA levels by 95% by month 3.
FIRMAGON is proven to maintain PSA suppression through 12 months of treatment
PSA level is a nonspecific measurement that may indicate cancer progression. These results should be evaluated with caution because of the broad range of patient types in the clinical study. No evidence has shown that the speed at which PSA declines is related to clinical benefit. Therefore, PSA level should not be seen on its own as evidence of the effectiveness of FIRMAGON.
Have A Voice
Every month is an opportunity for you to connect with your treatment team
Make monthly visits matter by getting involved in your treatment plan.